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ICERA consulting Ltd, Swindon, Wiltshire, UK; 2 Abacus International, Bicester, Oxfordshire, UK; 3 Pfi zer Limited, Tadworth, Surrey, UK OBJECTIVES: Behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) greatly increase caregiver burden and often trigger nursing home placement. a systematic review of double-blind randomized controlled trials (RCTs) was conducted to compare the ability of donepezil and memantine to manage BPSD in AD. METHODS: MEDLINE, EMBASE, Cochrane Library, and hand searches identifi ed 4739 citations, of which 16 studies had Neuropsychiatric Inventory (NPI) data suitable for meta-analysis (6 memantine and ten donepezil trials). All trials were placebo-controlled, and no head-to-head comparisons of the two drugs were identifi ed. a random-effects meta-analysis was conducted using AD severity subgroups to investigate heterogeneity between trials. Thereafter meta-regression was conducted using study level covariates as potential predictors of between-treatment weighted mean difference (WMD) in NPI score. RESULTS: Unadjusted random effects metaanalysis of all 16 RCTs found signifi cant between-study heterogeneity (all studies I 2 = 64.4%; donepezil vs. placebo WMD −1.84, 95%CI −3.57, −0.10, I 2 = 61%; memantine monotherapy vs. placebo WMD −1.19, 95% CI −3.70, 1.32, I 2 = 68.7%; memantine + AChEI combination therapy vs. placebo WMD −1.68 95% CI −5.70, 2.33, I 2 = 80.4%). Meta-regression that stratifi ed studies into four AD severity groups measured by Mini-Mental State Exam (MMSE) (severe 0-9, moderately-severe 10-14, moderate 15-20 and mild 21-26) and controlling for age at baseline, found these covariates accounted for most (59.85%) of the between-study variance. Using this meta-regression model, the pooled NPI score for donepezil showed signifi cant improvement compared to placebo (MD −1.50; 95% CI −2.63, −0.36) whereas this was not the case for memantine vs. placebo (MD −1.25; 95% CI −2.63, 0.13). CON-CLUSIONS: Donepezil was associated with signifi cant improvement in the management of BPSD in AD patients compared to placebo, whereas memantine failed to show a signifi cant improvement versus placebo in the management of these symptoms. To assess the all-cause medication discontinuation rate in matched cohorts of patients with schizophrenia at risk of nonadherence who were initiated on depot or oral antipsychotics and followed over 12 months. METHODS: At study entry, outpatients with schizophrenia from Australia, Mexico, Romania, and Taiwan were switched, due to clinician-perceived medication non-adherence risk, from their current oral antipsychotic to either a depot or different oral antipsychotic in this 12-month, prospective observational study. Patients were compared on all-cause medication discontinuation rates, defi ned as a switch from the initiated medication or its augmentation with another antipsychotic. Patients initiated on depot were matched with those initiated on any oral antipsychotic, using full optimal and nearest neighbour (greedy) matching algorithms. The Rank-based Mahalanobis metric was chosen as the distance based on propensity score plus other relevant covariates, with country and antipsychotic class used for exact matching. RESULTS: Based on the full optimal 1:1 matching, only 40 of the 43 original depot initiators were matched to a corresponding oral initiator. After matching, there were no statistically signifi cant differences between the depot and oral cohorts on any of the study entry covariates examined. During the 12-month study, 20% of depot patients discontinued their initial medication, compared with 40% of oral patients (survival curve comparison, p = 0.025; Hazard Ratio = 0.33 [0.12, 0.92], p = 0.033, NNT = 6 [3,-34]). No statistically signifi cant differences were found between the two groups on other assessed outcomes, including hospitalization, length of stay, and quality of life and disease severity measures. CONCLUSIONS: Systematic matching of patients initiated on depot with those initiated on oral antipsychotics showed that the oral-initiated patients were statistically signifi cantly more likely to discontinue their medication. Findings highlight the importance of systematic matching of patient cohorts when comparing treatment outcomes in observational studies. 
PMH2 COMPARING ALL-CAUSE MEDICATION DISCONTINUATION WITH DEPOT AND ORAL ANTIPSYCHOTICS IN MATCHED COHORTS OF PATIENTS WITH

PMH3 DETERMINANTS OF PSYCHIATRIC HOSPITAL ADMISSION IN
METHODS:
We followed 1460 study participants from baseline until fi rst schizophrenia-related hospital admission, study medication discontinuation, or 18 months.
Stepwise Cox regression models assessed the adjusted hazard ratio (AHR) of hospital admission by baseline patient socio-demographic and clinical characteristics. RESULTS: In 869 person-years of follow-up, 203 patients were hospitalized. The adjusted hazards of hospital admission were not signifi cantly related to patient socio-demographic characteristics. Increased risk of admission was linked to early age (<17 years) of fi rst antipsychotic treatment (AHR: 2.09; 95%CI: 1.45-3.02), psychiatric hospital admission in past year (AHR: 2.92; 95%CI: 2.18-3.90), and DSM-IV alcohol (AHR: 1.55; 95%CI: 1.15-2.08) and drug (AHR: 1.50; 95%CI: 1.13-2.00) use disorders in the past 5 years. Severe (5-7) as compared with mild (1-3) baseline global clinical severity (AHR: 1.51; 95%CI: 1.03-2.23) (CGI-I), high (>20) as compared with low (7-15) positive symptoms (AHR: 1.53; 95%CI: 1.08-2.16) (PANSS-positive subscale), and low (0-2.2) as compared with high (>3.1) social function (AHR: 1.47; 95%CI: 1.04-2.08) (Heinrichs-Carpenter QLI) were related to signifi cantly increased risk of hospital admission. As compared with olanzapine treatment assignment, quetiapine (AHR: 2.12; 95%CI: 1.37-3.27), perphenazine (AHR: 1.64; 95%CI: 1.02-2.65), and ziprasidone (AHR: 2.67; 95%CI: 1.62-4.39), though not risperidone (AHR: 1.40; 95%CI: 0.89-2.21), were also associated with increased hospital admission risk. Self-rated physical health (SF-12 PCS) and drug attitudes (DAI) were not signifi cantly related to risk. CONCLUSIONS: In the treatment of schizophrenia, efforts to lower hospital admission risk should focus on patients with early onset disorders, recent inpatient admissions, severe positive symptoms, high global clinical severity, poor social function, and comorbid substance use disorders and should select an appropriate antipsychotic medication.
PMH4 A PHASE IV STUDY OF THE EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE 600 MG ONCE A DAY TO CONTROL THE SYMPTOMS OF MANIC PHASE OF BIPOLAR DISORDER: THE EMMY TRIAL
Segovia M 1 , Polanco AC 1 , Anaya P 1 , López RJ 1 , Gutiérrez D 2 1 AstraZeneca, Naucalpan, Mexico; 2 National Institute of Psychiatry, D.F., Mexico OBJECTIVES: To assess the effi cacy of a 600 mg/day dose of Quetiapine Extended Release administrated once a day at evening as monotherapy or in combination with lithium or valproate for 21 days. METHODS: A multi-center phase IV study was designed to assess the effi cacy of quetiapine extended release 600 mg per day either as monotherapy or combined therapy with lithium and valproic acid in the treatment
